Lipopolysaccharide-induced inhibition of transcription of tlr4 in vitro is reversed by dexamethasone and correlates with presence of conserved NFκB binding sites

Biochemical and Biophysical Research Communications

Volumn 432, Issue 2, 2013, Pages 256-261

  Bonin, Camila P ^a   Baccarin, Raquel Y A ^a   Nostell, Katarina ^b   Nahum, Laila A ^c,d   Fossum, Caroline ^b   De Camargo, Maristela M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d Mestrado em Tecnologia da Informação Aplicada a Biologia Computacional   (Brazil)

Author keywords

Dexamethasone; LPS; MD2; NF B binding sites; TLR4; Transcriptional regulation

Indexed keywords

BIOLOGICAL FACTOR; CLUSTER OF DIFFERENTIATION 14; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; CHIMPANZEE; COMPUTER MODEL; CONTROLLED STUDY; GENETIC REGULATION; GENETIC TRANSCRIPTION; GENOME; HUMAN; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE BINDING SITE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; SEPTIC SHOCK; TRANSCRIPTION INITIATION SITE;

ANIMALS; ANTIGENS, CD14; BASE SEQUENCE; BINDING SITES; CATTLE; CONSERVED SEQUENCE; DEXAMETHASONE; HORSES; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MICE; NF-KAPPA B; PAN TROGLODYTES; PROMOTER REGIONS, GENETIC; RATS; SWINE; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION, GENETIC;

EQUIDAE; PAN; RATTUS;

EID: 84875266862     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.002     Document Type: Article

References (31)

1. Moore J.N., Morris D.D. Endotoxemia and septicemia in horses: experimental and clinical correlates. J. Am. Vet. Med. Assoc. 1992, 200:1903-1914.
2. Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273:117-123.
3. Shuster R., Traub-Dargatz J., Baxter G. Survey of diplomates of the American College of Veterinary Internal Medicine and the American College of Veterinary Surgeons regarding clinical aspects and treatment of endotoxemia in horses. J. Am. Vet. Med. Assoc. 1997, 210:87-92.
4. Suzuki K., Tateda K., Matsumoto T., Gondaira F., Tsujimoto S., Yamaguchi K. Effects of interaction between Escherichia coli verotoxin and lipopolysaccharide on cytokine induction and lethality in mice. J. Med. Microbiol. 2000, 49:905-910.
5. Soop A., Sunden-Cullberg J., Albert J., Hallstrom L., Treutiger C.J., Sollevi A. Adenosine infusion attenuates soluble RAGE in endotoxin-induced inflammation in human volunteers. Acta Physiol. (Oxf.) 2009, 197:47-53.
6. Morris D.D., Crowe N., Moore J.N. Correlation of clinical and laboratory data with serum tumor necrosis factor activity in horses with experimentally induced endotoxemia. Am. J. Vet. Res. 1990, 51:1935-1940.
7. Schumann R.R., Leong S.R., Flaggs G.W., Gray P.W., Wright S.D., Mathison J.C., Tobias P.S., Ulevitch R.J. Structure and function of lipopolysaccharide binding protein. Science 1990, 249:1429-1431.
8. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
9. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
10. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 1999, 189:1777-1782.
11. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 1999, 162:3749-3752.
12. Nomura F., Akashi S., Sakao Y., Sato S., Kawai T., Matsumoto M., Nakanishi K., Kimoto M., Miyake K., Takeda K., Akira S. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J. Immunol. 2000, 164:3476-3479.
13. Goldring C.E., Reveneau S., Pinard D., Jeannin J.F. Hyporesponsiveness to lipopolysaccharide alters the composition of NF-kappaB binding to the regulatory regions of inducible nitric oxide synthase gene. Eur. J. Immunol. 1998, 28:2960-2970.
14. Kastenbauer S., Ziegler-Heitbrock H.W. NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect. Immun. 1999, 67:1553-1559.
15. Ziegler-Heitbrock H.W., Wedel A., Schraut W., Strobel M., Wendelgass P., Sternsdorf T., Bauerle P.A., Haas J.G., Riethmuller G. Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J. Biol. Chem. 1994, 269:17001-17004.
16. Werners A.H., Bull S., Vendrig J.C., Smyth T., Bosch R.R., Fink-Gremmels J., Bryant C.E. Genotyping of Toll-like receptor 4, myeloid differentiation factor 2 and CD-14 in the horse: an investigation into the influence of genetic polymorphisms on the LPS induced TNF-alpha response in equine whole blood. Vet. Immunol. Immunopathol. 2006, 111:165-173.
17. Ohto U., Yamakawa N., Akashi-Takamura S., Miyake K., Shimizu T. Structural analyses of human Toll-like receptor 4 polymorphisms D299G and T399I. J. Biol. Chem. 2012, 287:40611-40617.
18. Hubbard T.J., Aken B.L., Ayling S., Ballester B., Beal K., Bragin E., Brent S., Chen Y., Clapham P., Clarke L., Coates G., Fairley S., Fitzgerald S., Fernandez-Banet J., Gordon L., Graf S., Haider S., Hammond M., Holland R., Howe K., Jenkinson A., Johnson N., Kahari A., Keefe D., Keenan S., Kinsella R., Kokocinski F., Kulesha E., Lawson D., Longden I., Megy K., Meidl P., Overduin B., Parker A., Pritchard B., Rios D., Schuster M., Slater G., Smedley D., Spooner W., Spudich G., Trevanion S., Vilella A., Vogel J., White S., Wilder S., Zadissa A., Birney E., Cunningham F., Curwen V., Durbin R., Fernandez-Suarez X.M., Herrero J., Kasprzyk A., Proctor G., Smith J., Searle S., Flicek P. Ensembl 2009. Nucleic Acids Res. 2009, 37(2009):D690-697.
19. I. Ratnere, I. Dubchak, Obtaining comparative genomic data with the VISTA family of computational tools, Curr. Protoc. Bioinformatics Chapter 10 (2009) Unit 10 16. http://dx.doi.org/10.1002/0471250953.bi1006s26.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
21. Sherwin R.L., Garcia A.J., Bilkovski R. Do low-dose corticosteroids improve mortality or shock reversal in patients with septic shock? A systematic review and position statement prepared for the American Academy of Emergency Medicine. J. Emerg. Med. 2012, 43:7-12.
22. Sligl W.I., Milner D.A., Sundar S., Mphatswe W., Majumdar S.R. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin. Infect. Dis. 2009, 49:93-101.
23. O'Neill L.A. How Toll-like receptors signal: what we know and what we don't know. Curr. Opin. Immunol. 2006, 18:3-9.
24. Banerjee A., Gerondakis S. Coordinating TLR-activated signaling pathways in cells of the immune system. Immunol. Cell Biol. 2007, 85:420-424.
25. Monie T.P., Bryant C.E., Gay N.J. Activating immunity: lessons from the TLRs and NLRs. Trends Biochem. Sci. 2009, 34:553-561.
26. McCoy C.E., Carpenter S., Palsson-McDermott E.M., Gearing L.J., O'Neill L.A. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation. J. Biol. Chem. 2008, 283:14277-14285.
27. Foteinou P.T., Calvano S.E., Lowry S.F., Androulakis I.P. In silico simulation of corticosteroids effect on an NFkB-dependent physicochemical model of systemic inflammation. PLoS One 2009, 4:e4706.
28. Medvedev A.E., Henneke P., Schromm A., Lien E., Ingalls R., Fenton M.J., Golenbock D.T., Vogel S.N. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J. Immunol. 2001, 167:2257-2267.
29. Tissieres P., Dunn-Siegrist I., Schappi M., Elson G., Comte R., Nobre V., Pugin J. Soluble MD-2 is an acute-phase protein and an opsonin for gram-negative bacteria. Blood 2008, 111:2122-2131.
30. Yan Q., Carmody R.J., Qu Z., Ruan Q., Jager J., Mullican S.E., Lazar M.A., Chen Y.H. Nuclear factor-kappa B binding motifs specify Toll-like receptor-induced gene repression through an inducible repressosome. Proc. Natl. Acad. Sci. USA 2012, 109:14140-14145.
31. Bolker J. Model organisms: there's more to life than rats and flies. Nature 2012, 491:31-33.